FROM THE START
of effective Microbiome Therapeutics following fecal transplant studies at AMC in Amsterdam (Vrieze et al., 2012)
on Microbiota-based concepts for prevention and early treatment of T2D.
from Academic Medical Center (AMC) in Amsterdam and Wageningen University in the Netherlands.
of the lead product E. hallii in a clinical trial in Metabolic Syndrome showing increased insulin sensitivity. This implies reduced risk of developing diabetes.
based on FMT resulting in new leads in Diabetes, Cachexia and Auto-immune diseases
Development of a broad range of microbiota based products and innovative formulations for prevention and early treatment.